pfizer

Pfizer, BioNtech plan to take emergency steps to use Covid-19 vaccine in December.

  • Pfizer ‘s Chief Executive Officer Albert Bourla has said the drug makers’ this move marks an important milestone.
  • The US drugmaker and its German partner said earlier this week that a final analysis of clinical trial data showed the shot was 95% effective in preventing the disease.

[avatar user=”Apoorva Garg” size=”thumbnail” align=”left”]by Apoorva Garg[/avatar]

Covid-19 vaccine manufacturers Pfizer Inc. and BioNtech SE said on Friday that they plan to file for an Emergency Use Authority that could allow their Covid-19 vaccine to be used in the US next month.

For an pandemic-affected world, the US drugmaker and its German partner confirmed earlier this week that a final analysis of clinical trial data showed the shot was 95% effective in preventing the disease.

The companies said in a statement that filing with the Food and Drug Administration could allow the vaccine to be administered to high-risk populations in the US by the end of December.

Also read- Netflix hires NBC scripted exec Tracey Pakosta as new head of comedy

In their application, Pfizer Inc. and BioNtech SE have also included safety data on approximately 100 children between the ages of 12–15. The company said that, 45% of US trial participants are 56–85 years old.

Also read- Indian Air Force Fighter Plane: Passengers kept staring

Pfizer’s Chief Executive Officer Albert Bourla has said the drug makers’ this move marks an important milestone.

Albert Bourla said in a statement that, “Filling in the US represents an important milestone in our journey to deliver the Covid-19 vaccine to the world and we now have a more clear picture of both efficacy and safety profiles”.